|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiao S, Liao S, Zhou Y, Jiang B, Li Y and
Xue M: High expression of octamer transcription factor 1 in
cervical cancer. Oncol Lett. 7:1889–1894. 2014.PubMed/NCBI
|
|
5
|
Zhang J, Jia J, Zhao L, Li X, Xie Q, Chen
X, Wang J and Lu F: Down-regulation of microRNA-9 leads to
activation of IL-6/Jak/STAT3 pathway through directly targeting
IL-6 in HeLa cell. Mol Carcinog. 55:732–742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bosch FX, Lorincz A, Munoz N, Meijer CJ
and Shah KV: The causal relation between human papillomavirus and
cervical cancer. J Clin Pathol. 55:244–265. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yee GP, de Souza P and Khachigian LM:
Current and potential treatments for cervical cancer. Curr Cancer
Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Green JA, Kirwan JM, Tierney JF, Symonds
P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence
after concomitant chemotherapy and radiotherapy for cancer of the
uterine cervix: A systematic review and meta-analysis. Lancet.
358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Keys HM, Bundy BN, Stehman FB, Muderspach
LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin,
radiation, and adjuvant hysterectomy compared with radiation and
adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl
J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mayr NA, Huang Z, Wang JZ, Lo SS, Fan JM,
Grecula JC, Sammet S, Sammet CL, Jia G, Zhang J, et al:
Characterizing tumor heterogeneity with functional imaging and
quantifying high-risk tumor volume for early prediction of
treatment outcome: Cervical cancer as a model. Int J Radiat Oncol
Biol Phys. 83:972–979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invasion, and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song X, Shi B, Huang K and Zhang W:
miR-133a inhibits cervical cancer growth by targeting EGFR. Oncol
Rep. 34:1573–1580. 2015.PubMed/NCBI
|
|
14
|
Chen Y, Ma C, Zhang W, Chen Z and Ma L:
Down regulation of miR-143 is related with tumor size, lymph node
metastasis and HPV16 infection in cervical squamous cancer. Diagn
Pathol. 9:882014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu L, Wang YL and Wang JF: Differential
expression of miR-21, miR-126, miR-143, miR-373 in normal cervical
tissue, cervical cancer tissue and Hela cell. Sichuan Da Xue Xue
Bao Yi Xue Ban. 43:536–539. 2012.(In Chinese). PubMed/NCBI
|
|
16
|
Moreno-Moya JM, Vilella F and Simón C:
MicroRNA: Key gene expression regulators. Fertil Steril.
101:1516–1523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vasudevan S, Tong Y and Steitz JA:
Switching from repression to activation: microRNAs can up-regulate
translation. Science. 318:1931–1934. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. 96
Suppl:R40–R44. 2007.PubMed/NCBI
|
|
22
|
Fan W, Huang J, Xiao H and Liang Z:
MicroRNA-22 is downregulated in clear cell renal cell carcinoma,
and inhibits cell growth, migration and invasion by targeting PTEN.
Mol Med Rep. 13:4800–4806. 2016.PubMed/NCBI
|
|
23
|
Shi C and Zhang Z: MicroRNA-362 is
downregulated in cervical cancer and inhibits cell proliferation,
migration and invasion by directly targeting SIX1. Oncol Rep.
37:501–509. 2017.PubMed/NCBI
|
|
24
|
Zhang S, Zhao Y and Wang L: MicroRNA-198
inhibited tumorous behaviors of human osteosarcoma through directly
targeting ROCK1. Biochem Biophys Res Commun. 472:557–565. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Flavin RJ, Smyth PC, Laios A, O'Toole SA,
Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J, et al:
Potentially important microRNA cluster on chromosome 17p13.1 in
primary peritoneal carcinoma. Mod Pathol. 22:197–205. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu J, Ye Q, Chang L, Xiong W, He Q and Li
W: Upregulation of miR-195 enhances the radiosensitivity of breast
cancer cells through the inhibition of BCL-2. Int J Clin Exp Med.
8:9142–9148. 2015.PubMed/NCBI
|
|
28
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC,
Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits
tumor progression by targeting RPS6KB1 in human prostate cancer.
Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and
Qian B: MiR-195 suppresses non-small cell lung cancer by targeting
CHEK1. Oncotarget. 6:9445–9456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun N, Ye L, Chang T and Li X and Li X:
microRNA-195-Cdc42 axis acts as a prognostic factor of esophageal
squamous cell carcinoma. Int J Clin Exp Pathol. 7:6871–6879.
2014.PubMed/NCBI
|
|
31
|
Yang Y, Li M, Chang S, Wang L, Song T, Gao
L, Hu L, Li Z, Liu L, Yao J and Huang C: MicroRNA-195 acts as a
tumor suppressor by directly targeting Wnt3a in HepG2
hepatocellular carcinoma cells. Mol Med Rep. 10:2643–2648.
2014.PubMed/NCBI
|
|
32
|
Jia LF, Wei SB, Gong K, Gan YH and Yu GY:
Prognostic implications of micoRNA miR-195 expression in human
tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo Q, Wei C, Li X, Li J, Chen L, Huang Y,
Song H, Li D and Fang L: MicroRNA-195-5p is a potential diagnostic
and therapeutic target for breast cancer. Oncol Rep. 31:1096–1102.
2014.PubMed/NCBI
|
|
34
|
Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian
J and Weng Y: Upregulation of miR-195 increases the sensitivity of
breast cancer cells to Adriamycin treatment through inhibition of
Raf-1. Oncol Rep. 30:877–889. 2013.PubMed/NCBI
|
|
35
|
Guo H, Li W, Zheng T and Liu Z: MiR-195
targets HDGF to inhibit proliferation and invasion of NSCLC cells.
Tumour Biol. 35:8861–8866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang X, Wang Y, Lan H and Li J: MiR-195
inhibits the growth and metastasis of NSCLC cells by targeting
IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang JS, Chao CC, Su TL, Yeh SH, Chen DS,
Chen CT, Chen PJ and Jou YS: Diverse cellular transformation
capability of overexpressed genes in human hepatocellular
carcinoma. Biochem Biophys Res Commun. 315:950–958. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bao C, Wang J, Ma W, Wang X and Cheng Y:
HDGF: A novel jack-of-all-trades in cancer. Future Oncol.
10:2675–2685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang J, Ren H, Yuan P, Lang W, Zhang L
and Mao L: Down-regulation of hepatoma-derived growth factor
inhibits anchorage-independent growth and invasion of non-small
cell lung cancer cells. Cancer Res. 66:18–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ren H, Chu Z and Mao L: Antibodies
targeting hepatoma-derived growth factor as a novel strategy in
treating lung cancer. Mol Cancer Ther. 8:1106–1112. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee KH, Choi EY, Kim MK, Lee SH, Jang BI,
Kim TN, Kim SW, Kim SW, Song SK, Kim JR and Jung BC:
Hepatoma-derived growth factor regulates the bad-mediated apoptotic
pathway and induction of vascular endothelial growth factor in
stomach cancer cells. Oncol Res. 19:67–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li SZ, Zhao YB, Cao WD, Qu Y, Luo P, Zhen
HN, Chen XY, Yan ZF and Fei Z: The expression of hepatoma-derived
growth factor in primary central nervous system lymphoma and its
correlation with angiogenesis, proliferation and clinical outcome.
Med Oncol. 30:6222013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ke Y, Zhao W, Xiong J and Cao R:
Downregulation of miR-16 promotes growth and motility by targeting
HDGF in non-small cell lung cancer cells. FEBS Lett. 587:3153–3157.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou Y, Zhou N, Fang W and Huo J:
Overexpressed HDGF as an independent prognostic factor is involved
in poor prognosis in Chinese patients with liver cancer. Diagn
Pathol. 5:582010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Uyama H, Tomita Y, Nakamura H, Nakamori S,
Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, et al:
Hepatoma-derived growth factor is a novel prognostic factor for
patients with pancreatic cancer. Clin Cancer Res. 12:6043–6048.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yoshida K, Tomita Y, Okuda Y, Yamamoto S,
Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, et al:
Hepatoma-derived growth factor is a novel prognostic factor for
hepatocellular carcinoma. Ann Surg Oncol. 13:159–167. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tsai CC, Huang SC, Tai MH, Chien CC, Huang
CC and Hsu YC: Hepatoma-derived growth factor upregulation is
correlated with prognostic factors of early-stage cervical
adenocarcinoma. Int J Mol Sci. 15:21492–21504. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA,
Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497
promotes tumor growth and angiogenesis by targeting HDGF in
non-small cell lung cancer. Biochem Biophys Res Commun.
435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen B, Huang T, Jiang J, Lv L, Li H and
Xia S: miR-141 suppresses proliferation and motility of gastric
cancer cells by targeting HDGF. Mol Cell Biochem. 388:211–218.
2014. View Article : Google Scholar : PubMed/NCBI
|
